• Acceptable single screening test for IgA-deficient individuals with suspected celiac disease.
• Preferred screening test is Celiac Disease Reflexive Cascade (2008114) or Tissue Transglutaminase (tTG) Antibody, IgG (0056009). (IgA testing recommended to identify IgA deficiency.)
• May aid in monitoring adherence to gluten-free diet in celiac disease confirmed patients.
Semi-Quantitative Indirect Fluorescent Antibody
New York DOH Approval Status
Serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Effective November 14, 2011
Less than 1:10
The presence of endomysial antibodies IgG, may be useful in identifying IgA-deficient patients at risk for celiac disease. To establish the diagnosis of celiac disease, a positive result must be confirmed through a biopsy of the small intestine.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2005502||Endomysial Antibody, IgG||51699-7|
- Anti-Endomysial Antibodies
- EMA IgG
- Gluten-Sensitive Enteropathy Tests
- IgA Deficient Celiac Disease